

Brilliant Violet 711™ anti-human CD326 (EpCAM)

Catalog # / Size: 2221195 / 25 tests
2221200 / 100 tests

Clone: 9C4

Isotype: Mouse IgG2b, κ


Immunogen: DU.4475 breast carcinoma

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 711™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: Lot-specific



Human colon carcinoma cell line HT29 was stained with CD326 (EpCAM, clone 9C4) Brilliant Violet 711™ (filled histogram) or mouse IgG2b, κ Brilliant Violet 711™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: Additional reported applications (for the relevant formats) include: immunofluorescence and immunohistochemistry³.

Application References:
1. Strnad J, *et al.* 1989. *Cancer Res.* 49:314.
2. Munz M, *et al.* 2004. *Oncogene* 23:5748.
3. Rao CG, *et al.* 2005. *Int. J. Oncol.* 27:49.

Description: CD326 is also known as Ep-CAM, tumor associated calcium signal transducer 1, epithelial cell surface antigen, epithelial glycoprotein 2, EGP2, adenocarcinoma

associated antigen, and TROP1. CD326 is a type I transmembrane protein containing six disulfide bridges and one THYRO domain. This cell surface glycosylated 40 kD protein is highly expressed in bone marrow, colon, lung, and most normal epithelial cells and is expressed on carcinomas of gastrointestinal origin. Recently, it has been reported that CD326 expression occurs during the early steps of erythropoiesis. CD326 functions as a homotypic calcium-independent cell adhesion molecule and is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation. CD326 antigen is an immunotherapeutic target for the treatment of human carcinomas.

**Antigen
References:**

1. Strnad J, *et al.* 1989. *Cancer Res.* 49:314.
2. Munz M, *et al.* 2004. *Oncogene* 23:5748.
3. Rao CG, *et al.* 2005. *Int. J. Oncol.* 27:49.